scholarly journals Quality of life of long-term childhood survivors after autologous or allogeneic stem cell transplantation in Japan-A cross-sectional study

2018 ◽  
Vol 7 (3) ◽  
pp. 107-112 ◽  
Author(s):  
Yasushi Ishida ◽  
Iori Sato ◽  
Masami Inoue ◽  
Akira Hayakawa ◽  
Masaaki Shiohara ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Childhood Survivors

Impact of infantile short bowel syndrome on long-term health-related quality of life: a cross-sectional study

2012 ◽  
Vol 47 (7) ◽  
pp. 1309-1316 ◽  
Author(s):  
Joanne F. Olieman ◽  
Corine Penning ◽  
Marten J. Poley ◽  
Elisabeth M.W.J. Utens ◽  
Wim C.J. Hop ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cross Sectional Study ◽  
Health Related Quality ◽  
Sectional Study ◽  
Cross Sectional ◽  
Short Bowel ◽  
Related Quality ◽  
Health Related

scholarly journals Quality of life and long-term outcomes of octo- and nonagenarians following acute care surgery: a cross sectional study

2013 ◽  
Vol 8 (1) ◽  
pp. 23 ◽  
Author(s):  
Sayf Gazala ◽  
Yvonne Tul ◽  
Adrian Wagg ◽  
Sandy L Widder ◽  
Rachel G Khadaroo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Acute Care ◽  
Cross Sectional Study ◽  
Acute Care Surgery ◽  
Sectional Study ◽  
Long Term Outcomes ◽  
Cross Sectional ◽  
Care Surgery

Long-Term Survival and Quality of Life Assessment After Allogeneic Stem-Cell Transplantation; Comparable Results Following Myeloablative and Reduced-Intensity Conditioning,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4096-4096
Author(s):  
Avichai Shimoni ◽  
Eran Tallis ◽  
Noga Shem-Tov ◽  
Yulia Volchek ◽  
Ronit Yerushalmi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Myeloablative Conditioning ◽  
History Of ◽  
Disease Free ◽  
Reduced Intensity

Abstract Abstract 4096 Allogeneic stem cell transplantation (SCT) is a potentially curative therapy for patients (pts) with various hematological malignancies. SCT is associated with substantial mortality during the first 2 years after SCT whereas after 2 years survival curves often reach a plateau. However, late mortality and late events continue to cause treatment failures through the late post-transplant course. Quality of life (QoL) is increasingly recognized as an important long-term end-point. The pattern of late events and QoL has been reported following myeloablative conditioning (MAC) but is not well defined in the reduced-intensity (RIC) setting. To explore late outcomes we retrospectively analyzed SCT results in a cohort of 726 pts given allogeneic SCT between 1/2000 and 8/2009. Pts meeting standard eligibility criteria were given MAC (n=207) while pts considered at excessive risk for non-relapse mortality (NRM) were given fludarabine based RIC (n=385) or reduced-toxicity myeloablative conditioning (RTC, n=134). 246 pts were alive and disease-free 2 years after SCT. Their median age was 51 years (17–72). Diagnoses included AML/MDS (n=131), ALL (n=24), lymphatic diseases (n=48), CML/MPD (n=29), non-malignant (n=14). Donors were HLA-matched siblings (n=151), unrelated (n=91) or alternative donors (n=4). Conditioning was MAC (n=72), RIC (n=118) or RTC (n=56). At 2 years after SCT, 172 pts had a history of chronic GVHD, graded as moderate-severe (mod-sev) in 44% and 29% of pts after MAC and RIC/RTC, respectively (p=0.03). 68% and 43% of pts were still on immune suppressive therapy (IST) 2 years after SCT, respectively (p=0.001). With a median follow-up of 68 months after SCT (range, 25–140), the probability of pts surviving disease-free 2 years after SCT to remain alive and disease-free for the next 5 years was 84% (95CI, 75–93) and 82% (95CI, 75–89) after MAC and RIC/RTC, respectively (p=NS). There were 35 deaths beyond 2 years, 15 due to relapse and 20 due to NRM. NRM included 9 deaths due to second cancers; 2 due to relapse of a primary malignancy in pts transplanted for therapy related AML, 4 other solid tumors, 3 donor MDS/AML. 9 pts died of chGVHD/infections and 2 of myocardial infarction. In all, the cumulative incidence of late NRM was 7% (4–11), similar after MAC and RIC/RTC. However, more pts in the MAC group died of chGVHD/ infections (6.9% Vs 2.3%, p=0.08), while more pts in the RIC/RTC group died of second cancers (4.6% Vs 1.4%, p=NS). 24 pts relapsed, 25–102 months after SCT, cumulative incidence 11% (7–16); 9% after MAC and 11% after RIC/RTC (p=NS); 15 died, 9 are alive following further therapies. The kinetics of late relapses was similar with MAC and RIC/RTC. Advanced age (>55) and moderate-severe chGVHD were the most significant predicting factors for shortened survival. OS 5 years after the 2-year time-point was 77% and 89%, in the older and younger groups, respectively (p=0.05). OS was 78% and 90% in pts with and without mod-sev chGVHD, respectively (p=0.004). Multivariate analysis confirmed these as independent factors, HR 2.1 (p=0.07) and 2.6 (p=0.006), respectively. The conditioning regimen, disease type and status at SCT and donor type were not predictive. A history of mod-sev chGVHD predicted for NRM, HR 5.2 (p=0.001). Advanced disease status at SCT predicted for relapse risk, HR 2.6 (P=0.004). The cumulative probability of stopping IST by 8 years after MAC and RIC/RTC SCT was 59 and 75%, respectively (p=0.001). For patients who stopped IST the median duration of IST was 30 and 20 months, respectively (p=0.05). QoL was assessed by the EORTC QLQ-C30 questionnaire. Mean QOL score was 69, 66 and 65 after MAC, RIC and RTC, respectively. A low QOL score (20 points below median) was reported by 15%, 14% and 19%, respectively (p=NS). There was no difference in any of the other domains of QoL assessment as well. Multiple regression analysis identified continuous need IST and reporting depression as factors correlated with a low score while a healthy lifestyle (including return to work, physical and sexual activity) and academic education were associated with high score. In conclusion, the pattern of late outcome is similar after MAC and RIC/RTC. Late NRM is similar although chGVHD is less severe and the required duration of IST is shorter after RIC/RTC. This may lead to better QoL. Younger pts who are disease-free 2 years after SCT, particularly those with no mod-sev chGVHD can expect good long-term outcome and relatively good QOL. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Comparison of quality of life among long-term melanoma survivors and non-melanoma controls: a cross-sectional study

2017 ◽  
Vol 26 (7) ◽  
pp. 1761-1766 ◽  
Author(s):  
Rachel Isaksson Vogel ◽  
Lori G. Strayer ◽  
Leah Engelman ◽  
Heather H. Nelson ◽  
Anne H. Blaes ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional

scholarly journals Depression and quality of life in patients on long term hemodialysis at a national hospital in Ghana: a cross-sectional study

2018 ◽  
Vol 52 (1) ◽  
pp. 22 ◽  
Author(s):  
Vincent J Ganu ◽  
Vincent Boima ◽  
David N Adjei ◽  
Joana S Yendork ◽  
Ida D Dey ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
National Hospital ◽  
Cross Sectional

scholarly journals Time in Therapeutic Range, Quality of Life and Treatment Satisfaction of Patients on Long-Term Warfarin for Non-Valvular Atrial Fibrillation: A Cross-Sectional Study

2020 ◽  
Author(s):  
Diana-Leh-Ching Ng ◽  
Natasya Marliana Bt Abdul Malik ◽  
Chee-Shee Chai ◽  
Greta-Miranda-Kim-Choo Goh ◽  
Seng-Beng Tan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atrial Fibrillation ◽  
Therapeutic Range ◽  
Treatment Satisfaction ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Significant Difference

Abstract Background:The use of warfarin in patients with non-valvular atrial fibrillation (NVAF) can be challenging. In this study, we evaluate the time in therapeutic range (TTR), health-related quality of life (HRQoL) and treatment satisfaction of patients on long-term warfarin for NVAF. The HRQoL and treatment satisfaction were compared based on the TTR.Methods:A cross-sectional study was conducted among patients on warfarin for NVAF who attended the anticoagulant clinic of a tertiary cardiology referral center in Sarawak from 1st June 2018 to 31st May 2019. Patients’ TTR was calculated by using Rosendaal technique, while their HRQoL and treatment satisfaction were assessed by using Short Form 12 Health Survey version 2 (SF12v2) and Duke Anticoagulant Satisfaction Scale (DASS), respectively. Results: A total of 300 patients were included, with mean TTR score of 47.0 ± 17.3%. The physical component summary (PCS) and mental component summary (MCS) score of SF-12v2 were 47.0 ± 9.0 and 53.5 ± 9.6, respectively. The total score for DASS was 55.2 ± 21.3, while the score for limitations (L), hassles and burdens (H&B) and positive psychological impacts (PPI) were 18.0 ± 10.0, 15.6 ± 9.1 and 21.6 ± 5.9, respectively. Seventy-three (24.3%) patients had good TTR (≥ 60%), with mean of 70.2 ± 8.7%; while 227 (75.5%) patients with poor TTR had significantly lower mean of 39.5 ± 11.9% (p = 0.006). There was no significant difference in the score of PCS (p = 0.150), MCS (p = 0.919) and each domain of SF-12v2 (p = 0.184 – 0.684) between good and poor TTR, except for social functioning (p = 0.019). The total DASS score was also not significantly different between group (p = 0.779). Similar non-significant difference was also reported in all the DASS sub dimensions (p = 0.502 – 0.699).Conclusions:Majority of the patients on long-term warfarin for NVAF in the current study have poor TTR. Their HRQoL and treatment satisfaction are independent of their TTR. Achieving a good TTR do not compromise the HRQoL and treatment satisfaction. Therefore, appropriate measures should be taken to optimise INR control, failing which direct oral anticoagulant therapy should be considered.

Sign in / Sign up

Export Citation Format

Share Document